HAWPF (Haw Par) ROCE %: 6.17% (As of Dec. 2025)

What is Haw Par ROCE %?

Haw Par HAWPF 95 ROCE % is 6.17% as of Dec. 2025. GuruFocus rates HAWPF with a GF Score™ of 95/100 and a GF Value™ of $8.79. The stock has 3 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Haw Par's annualized ROCE % for the quarter that ended in Dec. 2025 was 6.17%.

Haw Par (OTCPK:HAWPF) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Haw Par ROCE % Related Terms

Haw Par ROCE % Historical Data

* Premium members only.

The historical data trend for Haw Par's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Haw Par ROCE % Chart

Haw Par Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

ROCE %

Get a 7-Day Free Trial

3.77

4.72

6.57

6.41

6.79

Haw Par Semi-Annual Data
	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24	Jun25	Dec25
ROCE %	Get a 7-Day Free Trial															6.91	7.18	5.99	7.58	6.17

95GF Score

Haw Par Corp Ltd HAWPF

ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Haw Par ROCE % Calculation

Haw Par's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2025 )		(A: Dec. 2024 )		(A: Dec. 2025 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2025 )		(A: Dec. 2024 )		(A: Dec. 2025 )
	=	219.394	/	( ( (3167.216 - 67.307)	+	(3422.876 - 62.964) )	/ 2 )
	=	219.394	/	( (3099.909	+	3359.912)	/ 2 )
	=	219.394	/	3229.9105
	=	6.79 %

Haw Par's ROCE % of for the quarter that ended in Dec. 2025 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2025 )		(Q: Jun. 2025 )		(Q: Dec. 2025 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2025 )		(Q: Jun. 2025 )		(Q: Dec. 2025 )
	=	202.026	/	( ( (3280.937 - 96.941)	+	(3422.876 - 62.964) )	/ 2 )
	=	202.026	/	( ( 3183.996	+	3359.912 )	/ 2 )
	=	202.026	/	3271.954
	=	6.17 %

(1) Note: The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.

Frequently Asked Questions Learn more about ROCE % →

What does a ROCE % of 6.17% mean?

Haw Par (HAWPF) has a ROCE % of 6.17% as of Dec. 2025.

Is Haw Par's ROCE % too high?

Haw Par's current ROCE % is 6.17%. The Drug Manufacturers industry median ROCE % is 7.00. Haw Par's value of 6.17% is 11.8% below this industry median. Overall, Haw Par has a GF Score™ of 95/100, reflecting its overall financial health beyond just this single metric.

How does Haw Par's ROCE % compare to LLY and JNJ?

Haw Par's ROCE % of 6.17% can be compared against companies in the Drug Manufacturers industry. The industry median ROCE % is 7.00. Haw Par's value of 6.17% is 11.8% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good ROCE % for a Drug Manufacturers company?

The median ROCE % among Drug Manufacturers companies is 7.00, based on 958 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Haw Par's current ROCE % of 6.17% is 11.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high ROCE % mean?

A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median ROCE % is 7.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Haw Par's current ROCE % is 6.17%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Haw Par stock overvalued right now?

Haw Par (HAWPF) has a current ROCE % of 6.17%. The stock's GF Value™ is $8.79, compared to a current price of $12.00 — trading 36.5% above its estimated fair value. The current ROCE % is 6.17% and 11.8% below the Drug Manufacturers industry median of 7.00. Haw Par's overall GF Score™ is 95/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is ROCE % calculated?

ROCE % is calculated from a company's financial statements. For Haw Par (HAWPF), the current ROCE % is 6.17% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Haw Par (HAWPF) Overvalued in 2026?

Based on GuruFocus' analysis, Haw Par stock appears to be overvalued. The current stock price of $12.00 is trading 36.5% above its estimated GF Value™ of $8.79.

Key valuation signals for HAWPF:

ROCE %: 6.17%
GF Value™: $8.79 vs. price of $12.00 (36.5% above fair value)
GF Score™: 95/100 with 3 warning signs
Industry Position: 11.8% below the Drug Manufacturers median

No single metric tells the full story. See the HAWPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Haw Par Business Description

Industry Healthcare Drug Manufacturers

Comparable Companies SGX:42C SGX:BFK LLY JNJ ABBV XSWX:ROP MRK LSE:AZN XSWX:NOVN OCSE:NOVO B AMGN GILD PFE BMY XPAR:SAN LSE:GSK TSE:4519 XTER:BAYN TSE:4578 TSE:4568

Other Exchanges H02:Singapore H4V:Germany

Address 401 Commonwealth Drive, No. 03-03 Haw Par Technocentre, Singapore, SGP, 149598

Website https://www.hawpar.com

Haw Par Corp Ltd is a drug manufacturing company that operates multiple brands. The company is to expand its core businesses through product brand extension, strategic alliances, and exploring potential acquisitions. Its operating segments include the Healthcare segment, Investments segment, Property segment, and Leisure segment. The company generates the majority of its revenue from the Healthcare segment. Its Healthcare segment manufactures and distributes topical analgesic products under the Tiger Balm and Kwan Loong brands. Geographically, it generates key revenue from the other ASEAN and other Asian countries.

95GF Score

Get the complete analysis for HAWPF

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$12.00

Price

$8.79

GF Value

View HAWPF Analysis

See ROCE % data for all stocks →